Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics. Inflammatory Bowel Diseases. 2024; 30:1678-1685.
.High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease. The American Journal of Gastroenterology (Elsevier). 2024; 119:1110-1116.
.Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory Bowel Diseases. 2024; 30:S55-S66.
.2024; 166:s-226-s-227.
. 958 ATTAINING EARLY ANTI-TNF EXPOSURE TARGETS IS ASSOCIATED WITH IMPROVED RATES OF ENDOSCOPIC HEALING AND TRANSMURAL HEALING IN CHILDREN WITH CROHN'S DISEASE. Gastroenterology.2024; 166:s-177-s-178.
. 748 EXTENSIVE PROTEOMIC ANALYSIS IDENTIFIES A CROHN'S DISEASE CORE PROTEOME AND ANTI-TNF TREATMENT RESPONSE PROFILE FOR CHILDREN WITH CROHN'S DISEASE. Gastroenterology.Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ Open. 2024; 14:e077193.
.Acute pancreatitis is associated with gut dysbiosis in children. Digestive and Liver Disease. 2024; 56:444-450.
. .Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports. 2023; 25:323-332.
.2023; 23:e3-e4.
. Acute pancreatitis is associated with gut dysbiosis in children. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].The Role of Therapeutic Drug Monitoring in Children. Gastroenterology Clinics of North America. 2023; 52:549-563.
.Racial Disparities in Pediatric Inflammatory Bowel Disease Care: Differences in Outcomes and Health Service Utilization Between Black and White Children. The Journal of Pediatrics. 2023; 260:113522.
.Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2023; 29:1342-1346.
.Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial. Gastroenterology. 2023; 165:149-161.e7.
.Transcriptome analysis in acute gastrointestinal graft-versus host disease reveals a unique signature in children and shared biology with pediatric inflammatory bowel disease. Haematologica: the hematology journal. 2023; 108:1803-1816.
.2023; 164:s-703.
. Su1884 ACUTE PANCREATITIS IS ASSOCIATED WITH GUT DYSBIOSIS IN CHILDREN. Gastroenterology.2023; 164:s-504-s-505.
. Su1013 EVALUATION OF INSURANCE TYPE ON PRIOR AUTHORIZATION (PA) DELAYS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS PRESCRIBED BIOLOGIC THERAPIES. Gastroenterology.2023; 164:s-188.
. 860 ANTIBIOTIC USE AMONG PEDIATRIC PATIENTS WITH PERIANAL COMPLICATIONS OF CROHN'S DISEASE IN A MULTICENTER COHORT: THE CASE FOR ANTIBIOTIC STEWARDSHIP. Gastroenterology.2023; 164:s-1477.
. 513 DISPARITIES IN OSTOMY CREATION FOR PERIANAL FISTULIZING COMPLICATIONS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE WITHIN A MULTI-INSTITUTIONAL COHORT. Gastroenterology.2023; 164:s-59.
. 347 DISEASE PROGRESSION PHARMACOKINETIC MODELING IMPROVES THE ACCURACY OF EARLY INFLIXIMAB CONCENTRATION TARGETS. Gastroenterology.Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2023; 21:1338-1347.
.Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Alimentary Pharmacology and Therapeutics. 2023; 57:524-539.
.Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply. Alimentary Pharmacology and Therapeutics. 2023; 57:567-568.
.Springer Nature; Springer Nature; 2023.
. Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. Pediatric Inflammatory Bowel Disease. :Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis. Health Expectations. 2022; 25:3105-3113.
.Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis. Journal of Crohn's and Colitis. 2022; 16:1735-1750.
.iBDecide: A web-based tool to promote engagement in shared decision-making among adolescents with ulcerative colitis. Patient Education and Counseling. 2022; 105:1628-1633.
.Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics. 2022; 55:593-603.
.Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn's Disease. The Journal of Pediatrics. 2022; 242:86-92.e3.
.2022; 162:s98-s99.
. BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB. Gastroenterology.2022; 162:s99-s100.
. PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS. Gastroenterology.2022; 162:s100.
. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Gastroenterology.2022; 28:s99-s100.
. PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS. Inflammatory Bowel Diseases.2022; 28:s100.
. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Inflammatory Bowel Diseases.2022; 28:s98-s99.
. BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB. Inflammatory Bowel Diseases.Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Inflammatory Bowel Diseases. 2021; 27:1045-1051.
.Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clinical Pharmacology and Therapeutics. 2021; 109:1639-1647.
.Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease. Pediatric Quality and Safety. 2021; 6:e400.
.2021; 160:s-145-s-146.
. 728 PLASMA PROTEOMIC RESPONSE SIGNATURE FOR CHILDREN RECEIVING INFLIXIMAB FOR CROHN'S DISEASE. Gastroenterology.2021; 160:s-145.
. 727 ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY). Gastroenterology.Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflammatory Bowel Diseases. 2021; 27:507-515.
.Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2021; 27:482-492.
.2021; 160:s75-s76.
. ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY). Gastroenterology.Mucosal Inflammatory and Wound Healing Gene Programs Reveal Targets for Stricturing Behavior in Pediatric Crohn's Disease. Journal of Crohn's and Colitis. 2021; 15:273-286.
.2021; 27:s55-s56.
. ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY). Inflammatory Bowel Diseases.A Micro-longitudinal Approach to Measuring Medication Adherence in Pediatric Inflammatory Bowel Diseases. Journal of Pediatric Gastroenterology and Nutrition. 2020; 71:366-370.
.The Gray Zone: Adolescent and Young Adult Decision Support Needs for Ulcerative Colitis. MDM Policy and Practice. 2020; 5:2381468320940708.
.2020; 158:s-233-s-234.
. 1160 REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES CRITICAL NEED FOR PRECISION DOSING SOFTWARE. Gastroenterology.2020; 158:s-967-s-968.
. Mo1895 POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB INDUCTION EXPOSURE PREDICT 1-YEAR STEROID-FREE CLINICAL REMISSION IN PEDIATRIC IBD. Gastroenterology.2020; 158:s-130-s-131.
. 613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE. Gastroenterology.2020; 158:s-187-s-188.
. 935 PRE-TREATMENT MUCOSAL INFLAMMATORY AND WOUND HEALING GENE PROGRAMS REVEAL MECHANISMS ASSOCIATED WITH FUTURE STRICTURING BEHAVIOR DURING FIVE YEAR FOLLOW-UP IN PEDIATRIC CROHN'S DISEASE. Gastroenterology.Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2020; 26:429-439.
.2020; 158:s112.
. 22 CHANGE IN FECAL CALPROTECTIN AND LACTOFERRIN PREDICT CLINICAL REMISSION FOLLOWING INDUCTION THERAPY WITH INFLIXIMAB IN PEDIATRIC CROHN’S DISEASE (CD). Gastroenterology.2020; 26:s68-s69.
. 22 CHANGE IN FECAL CALPROTECTIN AND LACTOFERRIN PREDICT CLINICAL REMISSION FOLLOWING INDUCTION THERAPY WITH INFLIXIMAB IN PEDIATRIC CROHN’S DISEASE (CD). Inflammatory Bowel Diseases.2020; 14:s127.
. DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease. Journal of Crohn's and Colitis.